Ceftizoxime

Bacterial resistance is a core challenge facing the global anti-infective therapy field. With their high stability against β-lactamases, third-generation cephalosporins occupy an irreplaceable clinical position in the treatment of moderate to severe bacterial infections. As a third-generation cephalosporin antibiotic, ceftizoxime exerts a bactericidal effect by inhibiting the biosynthesis of mucopeptides in bacterial cell walls. It has remarkable antibacterial activity against Gram-negative bacteria and covers some Gram-positive bacteria. Clinically, it is mainly used for the treatment of lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections caused by susceptible bacteria. It can also be used for meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae and uncomplicated gonorrhea. The applicable population covers adults and children aged 6 months and above, and it is a common choice for perioperative infection prevention.

The market demand for anti-infective drugs has been stable for a long time. As a clinically mature variety, ceftizoxime has maintained a global market size in the range of USD 1.2-1.5 billion in recent years, and the terminal sales in China's public medical institutions have been stable at more than RMB 3 billion, with the overall growth rate remaining at a steady level of 2%-4%. In terms of the competitive landscape, the domestic preparation market has formed a situation dominated by generic drugs, with more than 10 enterprises having passed the consistency evaluation. The selected price in centralized procurement has a maximum reduction of 90% compared with the original research product, further improving clinical accessibility; in the API segment, domestic enterprises account for more than 95% of the supply, and fully independent supply has been realized.

The original research enterprise of ceftizoxime is Fujisawa Pharmaceutical Co., Ltd. of Japan (now Astellas Pharma), with the original research trade name "Ceftizox". Its core compound patent expired globally in 2002. The main dosage form approved for the original research product is ceftizoxime sodium for injection, with common specifications including 0.5g, 1.0g and 2.0g. The original research ceftizoxime sodium for injection has been included in China's *Catalogue of Chemical Reference Preparations* and also included in the FDA Reference Preparations Catalogue. Up to now, there are more than 15 registration numbers of ceftizoxime sodium APIs on China's CDE API registration platform, most of which are in Status A, which can meet the domestic production demand for preparations. More than 20 domestic enterprises have obtained approval for the marketing of ceftizoxime sodium for injection. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for ceftizoxime, most of which are in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can effectively meet the full-process needs of pharmaceutical enterprises in quality research, impurity control, registration and declaration, etc.